Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Guggenheim analyst Yatin Suneja maintains AnaptysBio (NASDAQ:ANAB) with a Buy and raises the price target from $90 to $100.
Wells Fargo analyst Derek Archila maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and raises the price target from $51 ...
AnaptysBio (NASDAQ:ANAB) reported quarterly earnings of $0.52 per share which beat the analyst consensus estimate of $(1.42) by...
Stifel analyst Alex Thompson maintains AnaptysBio (NASDAQ:ANAB) with a Buy and raises the price target from $55 to $80.
New data reinforce rosnilimab's efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, includi...
Wedbush analyst David Nierengarten maintains AnaptysBio (NASDAQ:ANAB) with a Outperform and raises the price target from $45...
AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics...
Barclays analyst Etzer Darout initiates coverage on AnaptysBio (NASDAQ:ANAB) with a Overweight rating and announces Price Ta...
AnaptysBio plans to separate into Royalty Management Co. and Biopharma Co. by 2026, with each positioned for growth in distinct...
